Next 10 |
metamorworks/iStock via Getty Images The clinical-stage biotech company, Xynomic Pharmaceuticals (XYNO) announced that it closed a short-form merger with Xu-Nuo Pharma as part of its plans to go private. Xu-Nuo Pharma held ~98% of the outstanding common shares in Xynomic following a...
Headwinds The odds of a SPAC ultimately succeeding aren't good. Newly de-SPACed companies, those that have gone public via a deal with a special purpose acquisition company/SPAC, face brutal headwinds. Sorting through the carnage in data compiled by SPAC Research , 73% of these stocks h...
June 25, 2020 FN Media Group Presents USA News Group News Commentary Los Angeles, CA – June 25, 2020 – USA News Group – In a major step forward, engineers from MIT have designed nanoparticles that stimulate the immune system, helping it to attack tumo...
SHANGHAI, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast-T...
SHANGHAI, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced the dosing of the first Chinese patient in its on-going global pivotal Phase ...
RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced encouraging interim data from an ongoing Phase 1b study of its lead cand...
RALEIGH, N.C. and SHANGHAI, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced that Xynomic Research Institute (“XRI”) has successfully d...
RALEIGH, N.C. and SHANGHAI, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced that the Independent Ethics Committees at three leading Chinese cancer h...
RALEIGH, N.C. and SHANGHAI, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage U.S.-China oncology drug development company, announced that it has filed an application with the U.S. Food and Drug Adm...
RALEIGH, N.C. and SHANGHAI, July 30, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced that Xynomic has received approval from China’s National Medical ...
News, Short Squeeze, Breakout and More Instantly...
Xynomic Pharmaceuticals Holdings Inc Company Name:
XYNO Stock Symbol:
OTCMKTS Market:
SHANGHAI, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast-T...
SHANGHAI, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced the dosing of the first Chinese patient in its on-going global pivotal Phase ...
RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced encouraging interim data from an ongoing Phase 1b study of its lead cand...